The Role of Induced Sputum in Amiodarone-Associated Interstitial Lung Diseases

Cardiology ◽  
2006 ◽  
Vol 108 (4) ◽  
pp. 223-227 ◽  
Author(s):  
Elizabeth Fireman ◽  
Ian Topilsky ◽  
Sami Viskin ◽  
Israel E. Priel
Keyword(s):  
Lung Diseases ◽  
Interstitial Lung Diseases ◽  
Induced Sputum

scholarly journals Reply to Wand et al.: Role of Transbronchial Cryobiopsy in Interstitial Lung Diseases: An Ongoing Tale

2020 ◽  
Vol 201 (2) ◽  
pp. 260-261
Author(s):  
Arnaud Bourdin ◽  
Carey M. Suehs ◽  
Thomas V. Colby ◽  
Isabelle Vachier ◽  
Nicolas Molinari ◽  
...  
Keyword(s):  
Lung Diseases ◽  
Interstitial Lung Diseases

scholarly journals Extended Exhaled Nitric Oxide Analysis in Interstitial Lung Diseases: A Systematic Review

2020 ◽  
Vol 21 (17) ◽  
pp. 6187
Author(s):  
Paolo Cameli ◽  
Elena Bargagli ◽  
Laura Bergantini ◽  
Miriana d’Alessandro ◽  
Maria Pieroni ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Lung Diseases ◽  
Interstitial Lung Diseases ◽  
Exhaled Nitric Oxide ◽  
Inhalation Therapy ◽  
Asthmatic Patients ◽  
Promising Tool ◽  
Multiple Flows ◽  
Published Evidence

Fractional exhaled nitric oxide (FeNO) is a well-known and widely accepted biomarker of airways inflammation that can be useful in the therapeutic management, and adherence to inhalation therapy control, in asthmatic patients. However, the multiple-flows assessment of FeNO can provide a reliable measurement of bronchial and alveolar production of NO, supporting its potential value as biomarker also in peripheral lung diseases, such as interstitial lung diseases (ILD). In this review, we first discuss the role of NO in the pathobiology of lung fibrosis and the technique currently approved for the measurement of maximum bronchial flux of NO (J’awNO) and alveolar concentration of NO (CaNO). We systematically report the published evidence regarding extended FeNO analysis in the management of patients with different ILDs, focusing on its potential role in differential diagnosis, prognostic evaluation and severity assessment of disease. The few available data concerning extended FeNO analysis, and the most common comorbidities of ILD, are explored too. In conclusion, multiple-flows FeNO analysis, and CaNO in particular, appears to be a promising tool to be implemented in the diagnostic and prognostic pathways of patients affected with ILDs.

scholarly journals Smoking and interstitial lung diseases

2015 ◽  
Vol 24 (137) ◽  
pp. 428-435 ◽  
Author(s):  
George A. Margaritopoulos ◽  
Eirini Vasarmidi ◽  
Joseph Jacob ◽  
Athol U. Wells ◽  
Katerina M. Antoniou
Keyword(s):  
Lung Cancer ◽  
Chronic Obstructive Pulmonary Disease ◽  
Langerhans Cell Histiocytosis ◽  
Lung Diseases ◽  
Interstitial Lung Diseases ◽  
Lung Damage ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Pulmonary Langerhans Cell Histiocytosis

For many years has been well known that smoking could cause lung damage. Chronic obstructive pulmonary disease and lung cancer have been the two most common smoking-related lung diseases. In the recent years, attention has also focused on the role of smoking in the development of interstitial lung diseases (ILDs). Indeed, there are three diseases, namely respiratory bronchiolitis-associated ILD, desquamative interstitial pneumonia and pulmonary Langerhans cell histiocytosis, that are currently considered aetiologically linked to smoking and a few others which are more likely to develop in smokers. Here, we aim to focus on the most recent findings regarding the role of smoking in the pathogenesis and clinical behaviour of ILDs.

scholarly journals The Crucial Role of NLRP3 Inflammasome in Viral Infection-Associated Fibrosing Interstitial Lung Diseases

2021 ◽  
Vol 22 (19) ◽  
pp. 10447
Author(s):  
Wiwin Is Effendi ◽  
Tatsuya Nagano
Keyword(s):  
Viral Infection ◽  
Nlrp3 Inflammasome ◽  
Lung Diseases ◽  
Alveolar Epithelium ◽  
Interstitial Lung Diseases ◽  
Molecular Signaling ◽  
Intrinsic Factors ◽  
Matrix Deposition ◽  
Age Related

Idiopathic pulmonary fibrosis (IPF), one of the most common fibrosing interstitial lung diseases (ILD), is a chronic-age-related respiratory disease that rises from repeated micro-injury of the alveolar epithelium. Environmental influences, intrinsic factors, genetic and epigenetic risk factors that lead to chronic inflammation might be implicated in the development of IPF. The exact triggers that initiate the fibrotic response in IPF remain enigmatic, but there is now increasing evidence supporting the role of chronic exposure of viral infection. During viral infection, activation of the NLRP3 inflammasome by integrating multiple cellular and molecular signaling implicates robust inflammation, fibroblast proliferation, activation of myofibroblast, matrix deposition, and aberrant epithelial-mesenchymal function. Overall, the crosstalk of the NLRP3 inflammasome and viruses can activate immune responses and inflammasome-associated molecules in the development, progression, and exacerbation of IPF.

scholarly journals Questions of ethical regulation of immunobiological therapy of some occupational lung diseases

2021 ◽  
Vol 38 (3) ◽  
pp. 131-140
Author(s):  
L. A. Shpagina ◽  
L. A. Panacheva ◽  
E. V. Zolotukhina
Keyword(s):  
Lung Diseases ◽  
Occupational Diseases ◽  
Legal Regulation ◽  
Interstitial Lung Diseases ◽  
Production Factors ◽  
High Prevalence ◽  
Medical Documents ◽  
Occupational Lung Diseases ◽  
Medical Examinations

Objective. Taking into account a high prevalence of occupational pathology associated with the exposure of industrial aerosols, to analyze the principles of therapy used for patients with these diseases. Materials and methods. The regulating medical documents, the data of preventive medical examinations as well as the principles of therapy applied for patients with occupational diseases, which are presented in scientific literarure, are analyzed. Results. The role of harmful production factors in the formation of pneumoconiosis and alveolitis, which join the group of interstitial lung diseases (ILD), has been proved. The outcome of these occupational diseases is fibrosing alveolitis with the development of diffuse pulmonary fibrosis. In the treatment of ILD, immunobiological drugs (IBD) are used to suppress the immune processes selectively affecting the monoclonal antibodies, blocking of which interrupts inflammation and in 90 % of cases stops the further development of the disease. Conclusions. The use of immunobiological drugs in clinical practice should be carried out within the framework of ethical and legal regulation between the patient and the doctor.

The role of calcium metabolism assessment in the clinical setting of interstitial lung diseases

2021 ◽  
Author(s):  
Paolo Cameli ◽  
Carla Caffarelli ◽  
Miriana D'Alessandro ◽  
Laura Bergantini ◽  
Martina Armati ◽  
...  
Keyword(s):  
Clinical Setting ◽  
Calcium Metabolism ◽  
Lung Diseases ◽  
Interstitial Lung Diseases

Identifying pulmonary hypertension in newly recognized interstitial lung diseases – a role of new scoring system

2020 ◽  
Author(s):  
Małgorzata Sobiecka ◽  
Katarzyna Lewandowska ◽  
Jarosław Kober ◽  
Monika Franczuk ◽  
Agnieszka Skoczylas ◽  
...  
Keyword(s):  
Pulmonary Hypertension ◽  
Scoring System ◽  
Lung Diseases ◽  
Interstitial Lung Diseases ◽  
New Scoring
Sign in / Sign up

Export Citation Format

Share Document